Consort’s pipeline of new products is building and confirmation that DEV610 is Mylan’s generic Advair has added to the sense that a major growth inflection point is approaching. Set against this is an almost perennial feeling of being underwhelmed at the pace of progress and the delays of launches (viz DEV200). We also continue to have some lingering reservations over the Aesica deal. We nudge our EPS forecasts up by 4% and await further details on the shape and pace of the DEV610 roll out.
